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ABSTrAcT
Venous thrombosis (VT) is the third major cause of mortality in the world after heart attack and stroke. Its 
two major clinical manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE) which are serious 
medical conditions but often remain under-diagnosed. Although rate of occurrence of venous thrombosis in men is 
slightly higher, a number of studies have pointed out that woman poses higher risk of venous thromboembolism 
(VTE) compared to men at various stages of life. Risk of VTE increases in women’s life particularly with use of oral 
contraceptives, during pregnancy and with exogenous administration of hormones like in post-menopausal hormone 
therapy. Various reports show that these factors increase risk of DVT and PE by several folds. DVT is considered 
as an important cause of maternal death in western countries.  It is often asymptomatic and its signs and symptoms 
are similar to those of normal pregnancy.  The hormonal changes at various stages of life and less physical activity 
increase the risk of VTE by blood flow stasis. It is extremely important for women to know the stages of life 
when they are prone to develop VTE, about its prevention and treatment. Detailed studies on differences in clinical 
manifestations of VTE between men and women are lacking. This review focusses on assessing the increased risk 
of VTE and its prognosis in women based on available literature.
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1. InTroducTIon 
Venous thromboembolism (VTE) is a complex multi-
factorial disease which is fairly common in many populations 
and has high rate of recurrence. Annual incidence of VTE 
ranges from 1 per 1000 to 3 per 1000 in normal populations1. 
Recurrence rates of this disease are higher ranging from 3 per 
cent to 5 per cent, which mostly occurs in close proximity 
after stopping anti-coagulant treatment2. While deep vein 
thrombosis (DVT) refers to a clot formed in the vein of calf 
region deep in the leg which can block the flow of blood in 
the vein, PE  present a more serious condition wherein the 
blood clot breaks off and travels in the lung resulting in 
sudden cough, tightness in chest with pain and shortness of 
breath. Pulmonary embolism is a potentially fatal condition 
and can lead to sudden death of an individual. Approximately 
20 per cent - 25 per cent of all PE cases result in sudden death3.
Although such blood clots can occur in both men and 
women, there are many reports which cite the reasons of higher 
incidences of VTE in women. Although the overall rate of VTE 
incidence is higher in men compared to women, but the rate is 
significantly increased during the reproductive phase4. Women 
possessing gender specific risk factors show better prognosis 
of cerebral venous and sinus thrombosis (CVST) compared 
to men5. One recent study from Indian subcontinent revealed 
higher incidence of cerebral venous thrombosis (CVT) even 
in non-pregnant women6. Life cycle of women is divided 
into three phases; pre-reproductive, reproductive and post-
reproductive phase. They are exposed to several risk factors for 
VTE pre-disposition in all three stages of life (Fig. 1).  Many 
recent studies have shown the increased occurrence of various 
clinical manifestations of VTE in women on fertility treatment, 
during pregnancy and those undergoing hormone replacement 
therapy. Some of such recent studies and their key findings are 
as listed in Table 1.
2. common rISK fAcTorS for VTE
Venous thrombosis is believed to be a result of complex 
interaction between genetic and environmental risk factors. 
Apart from ethnicity and family history, risk of developing VTE 
increases with age. Risk of VTE increases rapidly after 45-50 
years of age and annual incidences rises to 5-6 per 1000 by the 
age of 80. With advancing age, there is a sharp rise in incidence 
of PE compared to DVT7. Major risk factors apart from age 
comprise of exogenous factors like surgery, immobility, trauma, 
long distance travel, hospitalisation etc.8 and endogenous 
factors like obesity, cancers, hyper-coagulation and genetically 
inherited risk factors. Exogenous factors restricted to women 
include pregnancy, use of oral contraceptives, hormones for 
infertility, and menopause related problems. 
3. GEndEr SpEcIfIc rISK fAcTorS for 
VTE
Influence of age and sex on VTE susceptibility has 
not been fully established, it has been reported that overall 
incidences of both DVT and PE markedly increases with age in 
both men and women9. Relatively higher risk of VTE has been Received : 27 June 2018, Revised : 18 April 2019 
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observed in women on oral contraceptives, those undergoing 
fertility treatment, during pregnancy and post partum period 
and in those undergoing hormone replacement therapy (as 
illustrated in Fig. 1).
3.1 use of oral contraceptives
Modern oral contraceptives are very effective. However, 
use of oral contraceptives may be associated with occurrence 
of VTE. Use of hormonal oral contraceptives increase the 
risk of VTE from 5 in 10,000 woman in non-users to 9-10 in 
10,000 woman in users10. Oral contraceptives were introduced 
in market as early as in 1960s. These contained high doses of 
hormones; estrogens and progesterone. First case of PE after 
use of oral contraceptives was observed in a nurse11. After this, 
several cases of myocardial infarction and ischemic stroke 
were reported in oral contraceptive users12.
Levels of estrogen and progesterone hormone content 
in the drugs affects risk levels. The concentration of 
procoagulant factors in blood of an individual rise with 
increase in the levels of hormones. Contraceptives used 
decades ago had higher doses of estrogens and hence the 
risk of developing VTE was also higher. Modern available 
drugs contain <50 µg of ethinyl estradiol and have a lower 
risk of developing VTE13. In a European study, when oral 
contraceptives (OCs) containing 30 µg ethinyl estradiol was 
compared with those containing 20 µg, a non-significant 
decline in VTE was observed10.
During 1990s, third generation pills having newer 
progestin component were introduced. They were less 
androgenic and had fewer adverse effects on cardiovascular 
system and metabolic activities. Later, regulatory authorities 
raised a high alert i.e. “pill scare” in 1995 wherein these 
pills were associated with increased risk of VTE. Followed 
by this alert, large number of women discontinued OCs and 
an abrupt rise in births and abortions were noted14. 
Increased risk of VTE has been directly associated 
with doses of estrogen15. Thus, oral contraceptives with 
lesser doses of estrogen and progestogen have been 
introduced in the market, which also impose a reduced 
risk of cardiovascular diseases. Few studies compare 
risk of VTE development amongst women taking new 
generation OCs which contain drospirenone compared 
to those consuming third generation OCs, however the 
results are not conclusive10. Both these studies showed 
no association between OCs containing drospirenone and 
VTE compared to other OCs. On the contrary, Lidegaard 
and co-workers reported a relative risk of 1.6 (95 per cent 
CI 1.3-2.1) comparing OCs containing drospirenone with 
OCs containing levonorgestrel16.
3.2 ovarian Stimulation
Ovarian stimulation is generally done for treatment 
of infertility. Women undergoing such treatment are at 
increased risk of developing venous thrombo-embolism. 
Infertility treatment also involves the use of combined 
hormonal contraception (CHC) for down-regulation or 
estrogen for preparing the endometrium for pregnancy, 
both of which could contribute to increased risk of venous 
thrombosis in women17. Several studies have been conducted 
to evaluate the changes that occur in coagulation cascade 
during ovarian stimulation. It has been demonstrated that the 
physiological levels of estrogens directly affects hemostasis 
and is responsible for increase in coagulation factors such as 
VWF, factor VIII, and fibrinogen. Also, levels of anticoagulant 
factors such as protein C, protein S and antithrombin reduce 
with increase in estrogen levels18. Rova and co-workers studied 
risk of VTE development in Swedish women conceiving 
through IVF. They showed that VTE risk is ~10 folds higher 
in women conceiving through IVF during first trimester of 
pregnancy. Venous thrombosis risk is ~100 times higher in 
women conceiving through IVF and developing ovarian 
hyperstimulation syndrome (OHSS). In contrast to this, 
women who conceive through IVF using frozen embryos are 
not at enhanced risk of VTE19. Thus, substantial evidence is 
figure 1. Acquired risk factors for VTE development in women at 
various stages of life.
Table 1. major finding in relation to venous thromboembolism (VTE) 
and its clinical manifestations (dVT/pE/cVT/SVT)
Key observations citation
Incidences of cerebral venous thrombosis (CVT) 
significantly higher in non-pregnant women
[6]
Higher Cerebral thrombosis and sinus thrombosis (CVST) 
prognosis in women with gender specific risk factors
[5]
Increase in coagulation factors and reduction in anti-
coagulation factors in women during ovarian stimulation
[16]
~10 times higher VTE risk after ovarian stimulation and 
conceiving through IVF
~100 higher risk of VTE in women conceiving through IVF 
and developing OHSS 
[18]
Incidences of DVT are ~3 fold higher in pregnant women [19]
Oral Contraceptive users has 6.3 fold increased risk of VTE
Oral hormone therapy increase risk by ~4folds
[50]
Relative risk of VTE increases in hormone users with factor 
V Leiden, prothrombin G20210A or blood group non-O and 
with family history
[52]
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available to conclude that ovarian stimulation increases the 
risk of venous thromboembolism.
3.3 pregnancy
Incidences of venous thrombosis are more common in 
pregnant women compared to non-pregnant women of same 
age. Pregnancy associated increased risk of venous thrombosis 
has been reported previously20. The incidences of DVT are 
approx. 0.5 to 1.0 per 1000 live births during prepartum and 
peripartum21. Overall rate of venous thrombosis in women 
increase during reproductive years compared to men4. One of 
the major causes of maternal mortality in western countries is 
PE whereas pregnancy associated DVT is the main cause of 
maternal morbidity22. A study in Scotland showed 62 cases of 
venous thrombosis out of over 72,000 deliveries in Scotland. 
The risk of venous thrombosis is increased by at least 10 
folds during delivery compared to nonpregnant women23. 
During pregnancy, DVT mostly occurs in left leg due to 
anatomic course of iliac vessels and is distributed equally 
in the three trimesters24. Pregnancy associated risk factors 
include immobilisation, chorioamnionitis, placental abruption, 
hypertension, preeclampsia, and fetal growth restriction25. 
Clinicians commonly use D-dimer test for the diagnosis of VTE 
as it has high sensitivity with moderate specificity and negative 
predictive values. During pregnancy, the D-dimer levels rise 
naturally with advancing gestation period and are highest 
during post natal period. Thus, diagnosis of VTE by D-dimer 
test during pregnancy is not reliable. Further investigations are 
needed to diagnose VTE during pregnancy. 
3.4 puerperium
Puerperium is the term given the period that starts from 
the completion of the third stage of labour upto six weeks 
after delivery. During this period, body tries to revert the 
anatomical and physiological changes in the body occurring 
during nine months of pregnancy. Risk of VTE is maximum 
in this period. Risk of developing DVT during the puerperium 
is significantly higher than antepartum26. If a pregnant mother 
suffers from DVT during pregnancy or puerperium, treatment 
is initiated using low molecular weight heparin (LMWH). This 
anticoagulant prevents the blood clot from getting bigger and 
does not harm the developing foetus as it cannot enter placenta. 
Moreover LMWH is safe for breast feeding mothers. However, 
the treatment usually lasts for entire pregnancy and puerperium. 
On the other hand, vitamin K antagonists such as warfarin can 
pass through placenta easily and thus can have adverse effects 
on pregnancy, such as miscarriage, premature delivery, low 
birth weight, developmental problem, neonatal bleeding and 
characteristic foetal embryopathy. Therefore, warfarin therapy 
is not recommended for VTE treatment during pregnancy27 
especially during first trimester when organogenesis is 
occurring as well as during puerperium.
3.5 Hormone replacement Therapy
Antifibinolytic drugs, such as tranexamic acid, are 
used for treatment of heavy menstrual bleeding (referred as 
menorrhagia). These drugs reduce bleeding by inhibition of 
endometrial clot-dissolving enzymes. Such drugs may possess 
a risk of developing blood clots in leg and lungs28 however 
results are contradictory29. Women suffering from menorrhagia 
are prescribed with tranexamic acid based drugs, which prevent 
the decomposition of fibrin in clotted blood leading to cessation 
of further bleeding. This inhibits dissolution of thrombi, thus 
making them more prone to thrombosis30,31. Menopause 
is marked as end of reproductive period. Postmenopausal 
hormone replacement therapy is prescribed for the treatment 
of menopausal symptoms. Estrogens form important part of 
hormone replacement therapy (HrT); however, their consistent 
and excessive use can increase risk of endometrial cancer. 
Therefore, it is often combined with progestin by clinicians. 
Risk of venous thrombosis is increased by 2 to 4 folds during 
hormone replacement therapy32,33. The risk is further increased 
in older and overweight women and also those with mutation 
in factor V Leiden and higher factor IX levels34. At the age 
of menopause, physiological aging occurs which itself is 
associated with increased plasma levels of blood coagulation 
factors, platelets and impairment of fibrinolytic mechanism35. 
The relative risk of thrombo-embolic events in women 
undergoing HrT also depends on dose and type of progestogen 
used. It has been observed that pregnane derivatives associated 
risks are higher than nor-testosterone derivatives36. In addition 
to dose, the route of administration affects the relative risk. Oral 
administration has been associated with higher risk compared 
to transdermal HrT37. 
3.6 VTE risk at menopausal Stage
No independent association between age at menopause 
and VTE risk has been reported so far. However, early and 
premature menopause reflects an adverse health status implying 
an accelerated aging process which involve premature 
cessation of ovarian activity38,39. This early aging process have 
been associated with increase in the incidences of age-related 
pathologies including arterial and venous disease40. 
4. rEcurrEncE rATE of VEnouS 
THromBoSIS 
Venous thrombosis is often fatal and majority of deaths 
occur amongst those suffering from PE. It has been estimated 
that around 20 per cent - 25 per cent of PE cases result in 
sudden death41. Venous thrombosis has high rates of recurrence 
and this is one of its most serious complications. Although 
men have higher rates of recurrent VTE than women but 
this sex difference remains unexplained. After completion of 
anticoagulant therapy following a VTE incidence, the risk of 
recurrence is highest during first year. recurrence can occur 
even after 10 years of initial event and also remains throughout 
lives42. Women undergoing HrT confer a higher risk of 
recurrent venous thrombosis43.
5. IncrEASE In VTE IncIdEncES AT HIGH 
AlTITudES!
Environment at high altitude wherein the air is thinner and 
the environment is very cold is itself a stressful condition for 
the body. A person needs to acclimatise to decreased oxygen 
availability (hypoxic conditions) and decreased temperature to 
stay healthy. This process of acclimatisation involved various 
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physiological and biochemical adaptations to enhance oxygen 
uptake from oxygen depleted environment and improve tissue 
delivery. Several independent studies establish that relative 
risk of occurrence of DVT and PE increases significantly at 
high altitude44,45. Thus, there is substantial evidence in favour 
of direct relationship between high altitude exposure and a 
hypercoagulable state, however the mechanism is unclear. 
Although no reports are available on risk of women developing 
VTE at high altitudes, however, with limited available 
evidences, one can presume that women with gender specific 
risk factors could be at several times higher risk of developing 
VTE at high altitudes. Thus women using OC’s, pregnant 
women and also those undergoing specific treatments such 
as ovarian stimulations or HrT should assess the risk before 
planning for high altitudes expeditions.
6. dVT dIAGnoSIS
Those presenting symptoms of DVT should undergo 
detailed assessment of risk factors with complete medical 
history as well as physical examination. The scores obtained 
after clinical probability algorithms help in categorising a 
person under low, intermediate or high risk zones46. This 
can further help in disease diagnosis and deciding treatment 
strategy. Usually clinicians opt for D-dimer test, compression 
ultrasound for lower extremities and venous ultrasound 
examination for VTE diagnosis. It is often difficult to diagnose 
DVT during pregnancy, as the symptoms such as leg swelling, 
dyspnea and chest pain are otherwise common during pregnancy 
period. Also, since the D-dimer concentrations increase with 
gestational age and are particularly raised during post partum 
period47, hence this test may give false positive results if used 
for VTE diagnosis. In such cases, other non-invasive tests 
such as compression ultrasound examination could be more 
accurate.
7. SAfETy prEcAuTIonS
Being overweight and leading a sedentary lifestyle 
increases risk of thrombosis. VTE risk assessment tools should 
be applied by clinicians to all patients. Formation of unwanted 
blood clots can be prevented to some extent by taking some 
easy precautions. These include drinking lots of fluids which 
keeps the body hydrated and maintains fluidity of blood. 
Also, wearing loose clothing allows easy movement of body. 
Intermittent walking and stretching of limbs help keep blood 
flowing through the veins. Pregnancy safe exercises are highly 
recommended to avoid incidences of VTE and one should stay 
as active as possible to avoid incidences of VTE. Heparin and 
LMWHs are used to treat and prevent VTE during pregnancy. 
These drugs are considered safe because they do not cross 
placenta and thus do not enter circulation of the baby in the 
uterus. The use of Heparin and LMWHs does not cause any 
birth defects and bleeding problems in the babies48.
Several reports cited in this review points that women at 
childbearing age, pregnancy, puerperium and lactation are at 
increased risk of VTE49. Women with a history of thrombosis 
should be extra precautions and may explore options of family 
planning. Traditional therapy methods like use of direct oral 
anticoagulants (DOACs) as well as vitamin K antagonists are 
often used to treat VTE because of limited advancements in this 
field. Since risk if VTE increases during HrT50, bioidentical 
hormone therapy via the transdermal route has been reported 
as the safest opportunity for hormone replacement therapy50,51. 
Further studies and trials for more optimal and safer treatment 
technologies are awaited. 
8. SummAry
Venous thrombo-embolism is a major health concern that 
affects millions of individuals every year. It has serious clinical 
consequences and is potentially fatal. Since, incidences of VTE 
can be silent and are mostly asymptomatic, public awareness 
pertaining to the prevention, causes and treatment is important. 
Women need to have valid information about the risks 
associated with the use of given oral contraceptives, ovarian 
stimulation, pregnancy and hormone replacement therapy. 
Systematic anticoagulation therapy can prevent progression of 
thrombus and PE.
More comprehensive data and experimental evidences 
are required to assess and establish the gender specific risks of 
VTE which could be helpful in its early and accurate diagnosis 
and treatment. Retrospective searching of large databases 
could be useful in establishing the links between occurrence of 
VTE with use of specific formulations of oral contraceptives 
and hormone replacement.
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